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Abstract
Purpose: To determine the mechanisms of Signal Transducer and Activator of Transcription 1 (Stat1)-associated
radioresistance developed by nu61 tumour selected in vivo by fractionated irradiation of the parental radiosensitive tumour
SCC61.
Materials and methods: Radioresistence of nu61 and SCC61 in vitro was measured by clonogenic assay. Apoptotic response
of nu61 and SCC61 cells to genotoxic stress was examined using caspase-based apoptotic assays. Co-cultivation of
carboxyﬂuorescein diacetate, succinimidyl ester (CFDE-SE)-labeled nu61 with un-labeled SCC61 was performed at 1:1
ratio. Production of interleukin-6, interleukin-8 and soluble receptor of interleukin 6 (IL6, IL8 and sIL6R) was measured
using Enzyme-Linked Immunosorbent Assay (ELISA).
Results: Radioresistant nu61 was also resistant to interferon-gamma (IFNg) and the death ligands of tumour necrosis factor
alpha receptor (TNFR) family when compared to SCC61. This combined resistance is due to an impaired apoptotic
response in nu61. Relative to SCC61, nu61 produced more IL6, IL8 and sIL6R. Using Stat1 knock-downs we demonstrated
that IL6 and IL8 production is Stat1-dependent. Treatment with neutralising antibodies to IL6 and IL8, but not to either
cytokine alone sensitised nu61 to genotoxic stress induced apoptosis.
Conclusion: Nu61, which over-expresses Stat1 pathway, is deﬁcient in apoptotic response to ionising radiation and
cytotoxic ligands. This resistance to apoptosis is associated with Stat1-dependent production of IL6 and IL8 and suppression
of 8, 9 and 3.
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Introduction
Tumour cells may acquire radioresistance using
multiple pathways including those which are in-
duced/altered by ionising radiation (IR) itself (Lee
and Bernstein 1993, Tyrsina et al. 2005, Otero et al.
2006). To investigate IR-induced tumour radio-
resistance, a radiosensitive human squamous cell
carcinoma tumour, SCC61, was passed and irra-
diated in vivo. Radioresistant tumours were selected
and a tumour cell line, nu61, was isolated (Khodarev
et al. 2004). Analysis of the differences in gene
expression between cells from differentially selected
tumours demonstrated up-regulation of the genes in
the Signal Transducer and Activator of Transcrip-
tion 1 (Stat1) signalling pathway in radioresistant
nu61 tumours compared with radiosensitive SCC61
tumours. Recently we and others reported that IR
up-regulates Stat1 and a Stat1-dependent pathway
in vitro and in vivo (Amundson et al. 2004,
Khodarev et al. 2007) and tumour cells resistant to
radiation are also resistant to interferon. These
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duced by interferons (IFN) and IR. We hypothesised
that the development of resistance to the constitu-
tively expressed Stat1 pathway in tumour cells is
associated with suppression of the Stat1-dependent
apoptotic pathways or/and clonal selection of the
cells resistant to Stat1-dependent apoptosis
(Khodarev et al. 2007). Next, taking into account
that the Stat1 pathway, at least in the context of
IFN-signalling, leads to the induction of multiple
cytokines, we hypothesised that some Stat1-
dependent, pro-survival genes might encode
soluble factors secreted by the Stat1 over-expressing
cells (Khodarev et al. 2004, Brown et al. 2004,
Lehrnbecher et al. 2008). Here we report that indeed
apoptotic response in nu61 is impaired resulting in
suppression of caspases 3, 7, 8 and 9. This impaired
response leads to the resistance not only to IFNs and
IR but also to death ligands of tumour necrosis
factor alpha receptor (TNFR) superfamily. We also
report that nu61 differentially express interleukin-6,
interleukin-8 and soluble receptor of interleukin 6
(IL6, IL8 and sIL6R) and this expression is Stat1-
dependent. Formation of IL6-IL8-dependent auto-
crine loops plays a role in nu61 resistance to IR and
cytotoxic cytokines. Combined suppression of IL6
and IL8 signalling by neutralising antibodies led to
sensitisation of nu61 to genotoxic stress. These data
suggest IL6 and IL8 as potential targets for tumour
radiosensitisation.
Materials and methods
Cell lines
SCC61 and nu61 were cultured in Dulbecco
modiﬁed Eagle’s Media (DMEM-F12) (Invitrogen,
CA, USA) supplemented with 20% fetal bovine
serum, 2 mM L-glutamine, 100 U/ml penicillin/
streptomycin. Cells were maintained at 378Ci na
humidiﬁed chamber with 7% CO2. Stat1 knock-
downs and control retroviral vector L4 (Clontech,
Palo Alto, CA, USA)-transfected cell lines of SCC61
and nu61 were generated as previously described
(Khodarev et al. 2007) and cultured as the parental
cell lines. Control vector (CV)-transfected nu61 was
named N1L4 (nu61-L4) and CV- transfected
SCC61-S1L4 (SCC61-L4). The corresponding cell
lines with Stat1 knock-downs were named as NKD
and SKD, respectively.
Reagents
Recombinant human tumour necrosis factor a
(TNFa) and propidium iodide (PI) were purchased
from Sigma (St Louis, MO, USA). Recombinant
human TNF-related apoptosis inducing ligand
(TRAIL) was purchased from Peprotech, Inc (Rocky
Hill, NJ, USA). Recombinant human interferon g
(IFN-g), interleukin-6 (IL6) and interleukin-8 (IL8)
neutralising antibodies were purchased from R and
D Systems (Minneapolis, MN, USA). Anti-Fas
(tumour necrosis factor receptor superfamily, mem-
ber 6; TNFRSF6) CH11 antibody was purchased
from Upstate (Charlottesville, VA, USA). Vybrant
CFDA-SE (carboxyﬂuorescein diacetate, succinimi-
dyl ester) cell tracer kit, Vybrant ﬂuoromethyl ketone
(FAM) caspase-8 assay kit, Vybrant FAM caspase-3
and -7 assay kits were purchased from Invitrogen
(Carlsbad, CA, USA). The caspase-9 detection
kit was purchased from Cell Technology, Inc.
(Mountain View, CA, USA). The active caspase-3
phycoerythrin (PE) conjugated monoclonal antibody
was from BD Pharmigen (San Jose, CA, USA).
Irradiation
Cells were irradiated using a GE Maxitron Generator
operating at 250 kV, 26 mA at a dose rate of 1.18 Gy/
min. Samples were collected after irradiation as
described in results.
Clonogenic survival assay
Clonogenic survival assay was performed as de-
scribed in (Salloum et al. 2000) and analysed as
described in (Weichselbaum and Beckett 1987, Hall
1988).
Flow cytometry
Data were collected on a ﬂuorescence-activated cell
sorting FACScan instrument using CellQuest Soft-
ware (Becton-Dickinson, Franklin Lakes, NJ, USA).
At least 10000 events were collected for each sample.
FlowJo Software (FlowJo, LLC, Ashland, OR, USA)
was used for data analysis. Experiments were
repeated 3–4 times per cell line with consistent
results.
Apoptosis/cell death detection assays
Cells were plated in six-well plates at 1610
5 cells/
well in growth medium. After 24 h, cells were left
untreated or treated with radiation, IFNg in desig-
nated concentrations (see Results), 10 ng/ml TNFa,
TRAIL, or Fas-activating antibody CH11. 24 or
48 h later cells were harvested, washed in cold
phosphate buffer saline (PBS) and stained for
5 min in 1 mg/ml propidium iodide (Sigma, St Louis,
MO, USA), followed by FACS analysis, to detect
late apoptotic or necrotic cells. Cells with active
caspase-3 were detected by analysing the ﬂuorescein
isothiocyanate (FITC)-positive population using
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to the manufacturer’s protocol. For measurement of
activation of caspases 8, 9 and 3/7 in cell cultures we
used luminescent-based Caspase-Glo
1 assays, pro-
vided by Promega (Madison, WI, USA).
Co-cultivation of nu61 and SCC61
In experiments where the cells are co-cultured in
physical contact with each other, nu61 were labeled
with CFDA-SE and placed in co-culture with
unlabeled SCC61 in a 1:1 ratio. Treatment with 3
Gy IR, 50 ng/ml IFNg and 10 ng/ml TNFa was
begun 24 h later and cells harvested for ﬂow
cytometry 48 h later.
Measurement of IL6, IL8 and sIL6R secretion in CV-
transfected and Stat1 knock-downed SCC61 and nu61
cell lines
S1L4, N1L4, SKD and NKD were plated at
concentrations of 0.3–0.5610
6 cells/well in six-well
plates with 2.0 ml of growth media. Some 18–24 h
later cells were irradiated, incubated for an addi-
tional 48 h and samples of conditioned media were
collected for ELISA analysis. In preliminary experi-
ments, we compared irradiation at 3 and 6 Gy and
found that in these conditions 3 Gy led to a more
pronounced induction of IL6, IL8 and sIL6R
(Khodarev et al. 2001). Therefore this dose (3 Gy)
was used in all subsequent experiments. Each cell
line was plated in three independent wells. ELISA
kits were obtained from R & D Systems (Minnea-
polis, MN, USA) and concentrations of IL6, IL8 and
sIL6R were determined according to manufacturer’s
instructions.
Neutralisating antibodies against IL6 and IL8
To determine the effect of neutralising antibodies
(N-Ab) against IL6 and IL8 on cell survival and IR-
resistance, 30,000 nu61 cells/well were plated on 96-
well plates. 24 hours later cells were treated with N-
Ab against IL-6 (1 mg/ml, R & D Systems), IL8
(20 mg/ml, R & D Systems), or both, 4 h before
treatment with IR or IFNg (50 ng/ml). 24–48 h after
treatment, caspase 3 and 7 activation were deter-
mined using Caspase-Glo
1 assay (Promega) and by
FACS analysis after cell staining with an antibody
speciﬁc for the active form of caspase-3.
Statistical analysis
All experiments were performed at least three times.
Quantitative data are presented as mean+SE.
Signiﬁcance of difference was estimated by Student’s
two-tailed t-test with cut-off p 0.05.
Results
Nu61 are more radioresistant in vitro compared to
SCC61 based on clonogenic survival assay
In our previous reports we demonstrated that the
nu61 tumour, selected from the SCC61 tumour by
in vivo fractionated irradiation, is more radioresistant
based on in vivo assays and overexpresses Stat1
(Khodarev et al. 2004, 2007). In the current
experiments we directly compared in vitro clono-
genic survival of SCC61 and nu61. It has been
shown previously that the parental SCC61 has very
low clonogenic ability (Quiet et al. 1991). We
therefore used a relatively low range of doses
(between 0 and 5 Gy). As is shown in Figure 1, the
major difference between the two cell lines was
observed between 0 and 2 Gy as a pronounced
shoulder in nu61. We used a biphasic model
described in (Hall 1988) and previously used by us
for correlation of tumour radioresistance in vitro and
in vivo (Weichselbaum and Beckett 1987). We found
that between 2 and 5 Gy, D0 values for SCC61 and
nu61 were 0.66þ/70.03 and 0.60þ/70.07, re-
spectively (mean+SE, p40.05). Extrapolation
number (n) was higher for nu61 compared to
SCC61 (3.46+2.36 and 1.43+0.14 respectively;
mean+SE) but these differences were also not
signiﬁcant (p40.05). However, estimation of D1 in
the dose range between 0 and 2 Gy revealed a
signiﬁcant difference between nu61 and SCC61
(2.75+0.03 and 0.99+0.03; p50.05). The larger
D1 value in nu61 may be attributed to increased
sublethal damage repair (Weichselbaum and Beckett
1987, Wang et al. 2008). Literature indicates that
sublethal damage repair is connected with increased
resistance to genotoxic stress associated with sup-
pressed apoptosis (Blenn et al. 2006, Hara et al.
2008).
Figure 1. Clonogenic survival of nu61 (black squares) and SCC61
(white diamonds). Cells were plated at P60 (three dishes per dose)
and 18 hours after plating irradiated as indicated in Methods. Data
were analysed as described in Methods (see also Results for details).
Experiments were repeated three times. Shown are mean values;
error bars-standard error (SE).
Tumour protection through suppressed apoptosis and IL6-IL8 423Nu61 demonstrates impaired apoptotic response to
ionising radiation and interferons
To test the hypothesis that the suppression of cell
death in nu61 following IR and IFNg is due to the
suppression of the apoptotic response located down-
stream from Stat1, we analysed cell death and the
apoptotic response in nu61 and SCC61 cell lines.
We used PI staining at 48 h as an index of total cell
death, and measured apoptosis by ﬂow cytometry for
detection of cells that express the proximal caspase-3
as described in Methods. All experiments were
repeated at least three times, and representative data
are shown. As shown in Figure 2A, ionising radiation
(6 Gy) induced 26.2% (23.3+8.3%) PI positive
cells in SCC61 and 13.3% (10.33+3.4%) PI
positive cells in nu61. Figure 2B shows the same
trend for the post-IR accumulation of caspase-3-
positive cells in SCC61 and nu61 (see Methods).
29.6% (27.5+2.9%) of caspase-3-positive cells
accumulated in SCC61 48 hours post-IR and only
10.3% (9.8+1.5%) in nu61 (p¼0.005). These data
show that the differences in post-irradiation survival
between nu61 and SCC61 are mediated by caspase-3
mediated apoptosis which is suppressed in nu61.
Figure 2 shows also the response of SCC61 and
nu61 to IFNg (50 ng/ml). Forty-eight hours following
50 ng/mlIFNg,64.8%(61+5.8%)ofPIpositivecells
were detected in SCC61 and only 12.2%
(13.8+1.3%; p50.0001) in nu61 (Figure 2A).
Accumulation of caspase-3-positive cells was simulta-
neous with PI-positive cells (Figure 2B). 48 hours post
IFNg treatment 20.4% (19.8+2.1%) of caspase-3-
positive cells were detected in SCC61 and only 6.93%
(7.3+1.5%) in nu61 (p¼0.03). Pretreatment of both
cell lines with the caspase-inhibitor Z-Val-Ala-Asp
(OCH3)-ﬂuoromethylketone (Z-VAD-FMK) abol-
ished apoptotic response to both IR and IFNg (data
not shown). We concluded from these experiments
that interferon and radiation- induced cell death can
be accounted for by activation of caspase-3-mediated
apoptosis, and the decrease in the apoptotic response,
at least in part, accounts for the suppressed sensitivity
to IFN and IR in nu61 relative to SCC61.
Resistance to IR and interferons correlates with the
resistance to death ligands
We next tested the hypothesis that resistance to
genotoxic stress and interferons correlates with the
resistance to death ligands of TNFR superfamily. We
studied the cytotoxic effects of TNFa, CH11 (FAS-
activating antibody) and TRAIL (TNF-related apop-
tosis inducing ligand) in nu61 and SCC61 cells. As is
shown in Figure 3, each ligand, as well as irradiation
and IFNg, led to signiﬁcant apoptotic death in
SCC61 compared to nu61 (signiﬁcance was esti-
mated by t-test with cut-off value of p50.05). Both
proximal caspases (CASP8 and CASP9) were acti-
vated in SCC61 compared with nu61, indicating that
both intrinsic and extrinsic pathways of apoptosis
(Kim 2005, Fulda and Debatin 2006) are functional
in the parental SCC61 cell line, but are suppressed in
nu61. Effector caspases 3/7 were also suppressed in
nu61 compared to SCC61 conﬁrming that the cell
death detected in our experiments is connected with
apoptosis. Similar data were detected in ﬂow cyto-
metry experiments (data not shown). These data
show that overall cell death induced by the TNFR
family ligands, IFNg and IR was mediated by
apoptosis in both cell lines and the resistance of
nu61 to IR, IFNs and the TNFR family ligands is due
to the suppression of apoptotic caspases 3, 8 and 9.
Co-cultivation of nu61 with SCC61 partially protects
SCC61 from apoptosis
In the next set of experiments, we co-cultivated
SCC61 with nu61 to see if SCC61 could be rescued
by the presence of proteins secreted by nu61. Nu61
Figure 2. Down-regulation of caspase-3 activation in nu61 results
in decreased cell death in response to treatment with IR and IFNg.
48 hours after a single dose of 6 Gy IR, or 50 ng/ml of IFNg nu61
and SCC61 cells were either stained with PI (panel A) as a
measure of cell death or active caspase-3 (panel B) to measure
apoptosis. Nu61 cells demonstrate both reduced total cell death
(panel A) and apoptosis (panel B) compared to SCC61 in response
to IR and IFNg (see text for details). Shown are representative data
of three independent experiments.
424 E. V. Eﬁmova et al.cells were labeled with CFDA (see Methods) mixed
with unlabeled SCC61 at a 1:1 ratio, and 24 h later,
treated with IR (3 Gy), IFNg (50 ng/ml) or TNFa
(10 ng/ml). 48 h after treatment, cell death was
determined by PI staining using ﬂow cytometry.
Control experiments were run in which monocul-
tures of the same cell lines were subjected to the same
treatments. Figure 4A shows that in the co-culture
with nu61 SCC61 is more sensitive to cytotoxic
treatments than nu61, consistent with our previous
data. However, comparing the relative amount of cell
death of SCC61 in monoculture with SCC61 in co-
culture, we found that co-culture protects SCC61
from cytotoxic stimuli. Figure 4B show that treat-
ment by TNFa did not lead to signiﬁcant differ-
ence between SCC61 cultivated in mono-culture or
co-culture with nu61. However, treatment by IR led
to the signiﬁcant 5.5-fold protection (p¼0.023) and
treatment by 50 ng/ml of IFNg led to 1.6-fold
protection of SCC61 in co-culture relative to mono-
culture (p¼0.026: see Figure 4B). These data
suggested that nu61 can produce some secreted
factors, which provide protection of the parental
SCC61 cells from the cytotoxic insult.
Identiﬁcation of the pro-survival factors secreted by nu61
To identify pro-growth/pro-survival factors produced
by nu61, we performed pilot experiments using
Luminex technology (Levina et al. 2008). Out of 35
Figure 3. Proximal and effector caspases activation is suppressed
in nu61 compared to SCC61 in response to genotoxic stress and
death ligands of the TNF superfamily. Activation of the proximal
caspases of the extrinsic (panel B) and intrinsic (panel C)
apoptotic pathways, as well as the effector caspases-3 and -7
(panel A) common to both pathways were measured after
treatment with 10 ng/ml TNFa, 25 ng/ml CH11 (Fas-activating
antibody), 100 ng/ml TRAIL, 6 Gy IR or 50 ng/ml IFNg at 24 h
after treatment for caspases-8 and -9 and 48 h for caspases-3 and -
7. For all measurements we used Caspase-Glo
1 kits (see Methods).
Black bars represent SCC61, white bars represent nu61. Error bars
represent standard deviations (n¼3). p values are less than 0.05
for all graphs, representing signiﬁcant differences between SCC61
and nu61.
Figure 4. Interaction of nu61 and SCC61 cells partially protects
SCC61 from cell death and is associated with differential secretion
of IL6, sIL6R and IL8. Nu61 cells were labeled with CFDA-SE
(upper quadrants in panel A) to distinguish them from SCC61
(lower quadrants of panel A). Cells were co-cultured and treated
as described in Methods. Although nu61 do not completely rescue
SCC61 from cytotoxic treatments (panel A), SCC61 cells in co-
culture compared with SCC61 cells in monoculture (panel B) are
more resistant to cell death. Shown on panel B are mean values of
three independent experimentsþ/7SE.
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receptor (sIL6R) were differentially produced by
nu61 relative to SCC61 (data not shown). To
investigate the relative expression of IL6, IL8 and
sIL6R in nu61 and SCC61 we used ELISA (see
Methods). Since we were interested in the potential
relationships between Stat1 expression and the
expression of IL6, IL8 and sIL6R, we used stable
Stat1 knock-downs and CV-transfected cell lines of
SCC61 and nu61. We showed previously that stable
Stat1 knock-down by retroviral-based shRNA led to
2.5-fold suppression of Stat1 protein in NKD
relative to N1L4 (Khodarev et al. 2007). Further-
more we demonstrated that this knock-down leads to
signiﬁcant 1.9-fold radiosensitisation of N1L4
in vivo. These data indicated that some pro-
survival/radioprotective pathways may operate
down-stream from Stat1 (Khodarev et al. 2007).
We therefore suggested that IL6-IL8 signalling may
participate in these pathways. First we compared
production of IL6, IL8 and sIL6R by N1L4 relative
to S1L4 (control cell lines, see Methods). Figure 5A–
C shows that all three ligands were expressed in
N1L4 at the higher levels compared to S1L4. For
IL6 at the basal level the differences between S1L4
and N1L4 were highly signiﬁcant (6.9-fold increase
in N1L4; p50.00001). For IL8 there was a 4.1-fold
increase with signiﬁcance p¼0.0007. For sIL6R
N1L4 media was enriched by this ligand 2.4-fold
compared to S1L4 with p¼0.00057. Taken to-
gether, these data show that the nu61 phenotype is
associated with increased production of IL6, IL8 and
sIL6R compared to the parental SCC61 cell line.
Next we compared differences in the production of
IL6, IL8 and sIL6R in control cell lines (S1L4 and
N1L4) and the corresponding Stat1 knock-downs
(SKD and NKD, see Methods). Basal IL-6 produc-
tion in SKD was decreased compared to the S1L4
1.97-fold (p¼0.0004; see Figure 5A). For NKD/
N1L4 suppression of IL6 production was 1.3-fold
with p¼0.01 (see Figure 5A). This suggests that IL-6
production is Stat1-dependent in both cell lines. For
basal IL-8 production we did not detect any trends in
SCC61, perhaps due to the low sub-threshold
expression of this cytokine, but in nu61, we detected
signiﬁcant suppression of IL-8 production in NKD
relative to N1L4 (see Figure 5B). NIL4 produced
8785.7+695.8 pg/ml of IL-8, while NKD produced
only 6811.6+114 pg/ml. The difference was sig-
niﬁcant with p¼0.046. These data suggest that at
least in N1L4 IL8 production is also associated with
Stat1 expression, as is IL6 production (see above).
Finally we examined the effects of IR on the
expression of IL6, IL8 and sIL6R. As is shown in
Figure 5A, IL6 demonstrates clear up-regulation post
IR both in SIL4 and N1L4. For S1L4 on the basal
level the concentration of IL6 was equal to
78.1+2.92 pg/ml. 48 hours post-IR concentration
increased to 220.1+8.28 pg/ml. This indicates a 2.8-
fold induction with signiﬁcance p¼7.95E-05. In
N1L4 the basal concentration of IL6 was equal to
488.1+20.1 pg/ml. 48 hours post IR the concentra-
tion increased to 972.1+42.3 pg/ml (1.99-fold
induction; p¼0.00046). These data demonstrate that
IL6 production is induced by IR in both SIL4 and
N1L4 cell lines. Interestingly, together with IR-
induced up-regulation of IL6 in S1L4, we also
detected IR-induced up-regulation of sIL6R (see
Figure 5C). The basal concentration of sIL6R in
Figure 5. Production of IL6 (panel A), IL8 (panel B) and sIL6R
(panel C) by CV-transfected nu61 and SCC61 and cells with
stable Stat1 knock-down. Cells were plated in six-well plates and
24 hours later irradiated by 3 Gy as described in Methods. Each cell
line was plated in three independent wells. 48 hours conditioned
media was collected and used for estimation of concentrations of
IIL6, IL8 and sIL6R using ELISA kits (R & D Systems,
Minneapolis, MN, USA). See text for explanations. Error
bars¼SE.
426 E. V. Eﬁmova et al.S1L4 was 97.5þ/72.93 pg/ml. 48 hours post IR it
increased to 126.5 þ/78.4 pg/ml. The fold-induction
was relatively modest (1.3-fold) but statistically signi-
ﬁcant (p¼0.0297). Contrary to these observations, in
N1L4 irradiation shows a trend towards the suppres-
sion of sIL6R production (0.82-fold), but without
signiﬁcance (p¼0.1932). In other words, in S1L4, IR
led to the up-regulation of both IL6 and sIL6R, while
in N1L4, IR signiﬁcantly induced only IL6 produc-
tion, but not sIL6R. These data are consistent with
recent observations that shedding of IL6 receptor is
connected with activation of apoptosis (Chalaris et al.
2007).SensitivityofSCC61toapoptosis(see Figures 2
and 3) is also consistent with these data.
The data described in Figure 5 led to three
important conclusions. First, N1L4 overexpress
IL6, IL8 and sIL6R on the basal level compared to
the parental cell line S1L4. Pro-survival and anti-
apoptotic signalling connected with these cytokines
may at least in part explain the resistance of nu61 to
apoptosis compared to SCC61. Second, comparing
wild type (wt) and Stat1 KD variants of both cell
lines we found that both IL6 and IL8 production are
dependent on Stat1. To our knowledge this is the
ﬁrst observation that in SCC61/nu61 cell lines Stat1
expression is associated with production of IL6 and
IL8. Third, we found that IL6/sIL6R system is
clearly radioinducible in SCC61 (see Discussion).
Inactivation of IL6 and IL8 sensitises cells to genotoxic
stress and IFNg in nu61
To deﬁne the role of IL6 and IL8 in nu61 survival we
used neutralising antibodies to IL-8 and to IL-6
alone and in combination. Cells were treated with
neutralising antibodies (N-Ab) as described in the
Methods. As shown in Figure 6A, neither antibody
alone affected survival of nu61 after treatment with
IFNg alone or in combination with IR (see Methods).
However, the combination of both antibodies led to a
2-fold suppression of nu61 viability after treatment
with IFNg and a 1.9-fold suppression after combined
treatment with IR and IFNg. The signiﬁcance of
these observations was conﬁrmed by t-test with
p50.001 (Figure 6A). We investigated the action
of neutralising antibodies to IL-6 and IL-8 on the
activation of apoptotic caspases-3 in response to IR
and IFNg. As is shown in Figure 6B, neutralisation
of both IL6 and IL8 led to a 4-fold increase of
caspase-3-positive cells treated by the combination of
IR (3 Gy) and IFNg (50 ng/ml).
Our data indicate that treatment of parental
SCC61 with recombinant IL6 and IL8 led to partial
protection from IR-induced apoptosis (3 Gy) by
31.5% (not shown). Further experiments with stably
transfected cell lines are necessary to fully under-
stand the mechanisms of this protection.
Discussion
In previous reports we described the selection of a
human radioresistant, IFN-resistant tumour cell line,
nu61, by serial passage and fractionated irradiation
in nude mice. We showed that radioresistance of
nu61 is associated with the constitutive up-regulation
of the Stat1 pathway and Stat1-dependent, IFN-
stimulated genes (ISG) (Khodarev et al. 2004,
2007). We also showed that IR can directly activate
the Stat1 pathway and that selection of parental
interferon/radiosensitive tumours-SCC61 against in-
terferons leads to the selection of clones that are
cross-resistant to IR and IFN and over-express genes
Figure 6. Cell viability of nu61 cells is reduced by neutralising
antibodies to IL-6 and IL-8 and is associated with activation of
apoptotic cell death. Cells were treated with either IFNg (50 ng/
ml) alone or in combination with IR (6 Gy) (see Methods). The
antibodies to IL-6 and IL-8 together, but not alone, reduced
viability of nu61 in response to both IFNg alone and in
combination with IR, with signiﬁcance at p50.001 (panel A).
Data on panel A are normalised to the cells treated by 50 ng/ml of
IFNg, but not treated by neutralising Abs (indicated as no Ab on
X-axis). Staining for active caspase-3 (panel B) shows that
neutralising antibodies to IL-6 and IL-8 activate caspase-3 in
response to IFNgþ IR (representative data from three experi-
ments). Black bars on the panel 5A represent nu61 cells treated by
IFNg and combinations of neutralising Abs to IL6 and IL8. Grey
bars represent the same cells treated by the combination of IR and
IFNg. Error bars are standard deviations (n¼3) and asterisks
indicate pairs with p values 50.05.
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down leads to radiosensitisation of nu61 (Khodarev
et al. 2007). These observations suggested that
constitutive over-expression of the Stat1 pathway
leads to combined resistance to IFN and IR, and is
associated with Stat1-dependent pro-survival signal-
ling. However, the mechanisms of this cross-resis-
tance and pro-survival signalling remained elusive.
Cytotoxicity following Stat1 activation by interfer-
on stimulation is mediated by apoptosis (Samuel
1991). We therefore hypothesised that nu61 resis-
tance to genotoxic stress is mediated, at least in part
by resistance to apoptosis induction. Activation of the
apoptosis-associated caspases is the most common
hallmark of apoptotic celldeath (Eckelman et al. 2006,
Youle and Strasser 2008). Using various approaches
for the measurement of caspases 3, 7, 8 and 9 we
found that they were suppressed in nu61 relative to
the SCC61. These data indicate impaired apoptotic
response in nu61. This indicates that nu61 resistance
to genotoxic stress is located down-stream from
Stat1, contrary to the few reported cases of up-stream
resistance to IFN (Kaplan et al. 1998, Muller et al.
2005). Interestingly, according to clonogenic assay,
in the region of the initial slope (see Figure 1) the
number of clonogenic cells in nu61 exceeds that in
SCC61 by approximately two-fold. This is the inverse
of the proportion of caspase-3 positive apoptotic cells
in the short-term assay (see Figure 2). This suggests
that decreased apoptosis in nu61 may be connected
with increased proportion of apoptosis-resistant
clonogenic cells in nu61 population, which is con-
sistent with our results about increased production of
growth/proliferation-stimulating cytokines in nu61
(see below).
We further suggested that suppression of apoptotic
cell death in nu61 might lead to the increased
resistance of this cell line and corresponding tumours
to the death ligands of the TNFR superfamily, which
mostly operate through induction of apoptosis
(Varfolomeev et al. 2005, Dai et al. 2006, Baritaki
et al. 2007). Indeed, our results show that in addition
to IR and IFN resistance, nu61 relative to SCC61 is
also resistant to TNFa, TRAIL and FAS. All of these
ligands are known to be involved in the control of
tumour growth (Weichselbaum et al. 2002, Han
et al. 2008). It is possible that the selection of
radioresistant tumour clones induced by fractionated
irradiation is associated with suppression of apopto-
tic pathways activated by different pro-inﬂammatory
cytokines (Dunn et al. 2005).
Our previous data also indicated that in nu61 the
functions of Stat1 are connected with pro-survival
and radio/chemo-protective signalling (Khodarev
et al. 2007, Weichselbaum et al. 2008). We should
note that these observations are contradictory to
traditional understanding of Stat1 as tumour
suppressor gene (Samuel 2001, Levy and Darnell
2002). However, currently several laboratories have
conﬁrmed the association of Stat1 with an aggressive
chemo-/radio-resistant and oncogenic phenotype.
It has been shown that Stat1 can control essential
pro-survival genes, such as Myeloid Cell Leukemia 1
(MCL-1) (Timofeeva et al. 2006), Interferon-Induci-
ble Transmembrane Protein 1 (IFITM1) (Kita et al.
2003) and multi-drug resistance Major Vault Protein
MVP (Steiner et al. 2006). Constitutive over-expres-
sion of Stat1 and Stat1-dependent genes is associated
with protection of tumour cells from genotoxic stress
following treatment with ﬂudarabine (Friedberg et al.
2004), doxorubicin (Thomas et al. 2004), cis-
platinum (Roberts et al. 2005) and the combination
of ionising radiation and doxorubicin (Rickardson
et al. 2005, Fryknas et al. 2007). Most recently it was
demonstrated that suppression of Stat1 leads to
radiosensitisation in renal cell carcinoma (Hui et al.
2009), which is consistent with our previous observa-
tions (Khodarev et al. 2007). In the current report we
provide a partial mechanistic explanation for such a
‘reversed’ Stat1-dependent phenotype that is con-
nected with alterations in apoptosis. Another part of
an explanation may be connected with secretion of
Stat1-dependent pro-survival factors (Adams and
Cory 2002, Tan and Coussens 2007). To test this
hypothesis we established co-cultures of nu61 and
SCC61 (see Figure 4) and found that nu61 secretes
factors which partially rescue SCC61 from cell death.
We identiﬁed these factors as IL8, IL6 and the soluble
receptor of IL6 (sIL6R), which were differentially
secreted by nu61 compared to SCC61 (see Figure 5).
IL6 and IL8 signalling are recognised as important
factors of tumourogenesis (Bachelor and Bowden
2004, Hodge et al. 2005, Nicolini et al. 2006) and
may be associated with the Stat1 pathway through
glycoprotein 130 (gp130), CCAAT/enhancer binding
protein beta (C/EBP beta) and direct interaction of
Stat1 with IL8 promoter (Ernst and Jenkins 2004,
Yamaoka et al. 2004, Hu and Nicholas 2006,
Galdiero et al. 2006). Our experiments show that
expression of IL6 and IL8 is directly suppressed by
Stat1 knock-down (see Figure 5). These experiments
suggest that expression of these cytokines is controlled
by Stat1, but additional experiments are needed to
decode these relationships.
Of speciﬁc interest are our observations about
sIL6R. This receptor does not individually activate
down-stream signalling. Upon binding with IL6 it
further binds to the ubiquitous receptor gp130, and
activates Stat1/Stat3 pathways and pro-survival Ras
and Akt pathways (Ernst and Jenkins 2004). These
processes called ‘trans-signalling’ and solubilisation
(shedding) of sIL6R are associated with activation of
apoptosis (Chalaris et al. 2007). These data are
consistent with our observations presented in
428 E. V. Eﬁmova et al.Figure 4 and Figure 5 and suggest that nu61 cells
may not only promote their own growth and survival
but also form pro-survival paracrine loops, at least in
part involving IL8/IL6/sIL6R network.
Our experiments show that this phenotype can be
reversed with neutralising antibodies to IL6 and IL8
(see Figure 6). These results provide compelling
evidence that IL6-IL8 signalling is associated with
resistant phenotype of nu61.
Based on our results we hypothesise that Stat1,
IL6/sIL6Ra and IL8 form an interdependent net-
work associated with increased survival of nu61. The
parental tumour clone (SCC61) is subjected to
negative pressure from irradiation and/or the tumour
microenvironment which produce multiple factors
able to activate the Stat1 pathway (Nishigaki et al.
2006, Buess et al. 2007, Andersen et al. 2008).
Importantly, our data suggest that IR-induced up-
regulation of IL6 in parental SCC61 tumour cells
might be one of the initial events in the activation of
the Stat1 pathway (see Figure 5). This activation
leads to the elimination of the majority of the tumour
cells, sensitive to Stat1-delivered cytotoxicity but also
induces the selection of ‘nu61-like’ clones, which are
resistant to irradiation and the stromal death ligands
due to suppression of Stat1-dependent apoptotic
pathways. The ability of these cells to secrete pro-
survival ligands promotes growth and the transfor-
mation of surrounding less aggressive tumour or pre-
malignant clones. This selection leads to the forma-
tion of tumour clones with aggressive properties and
combined resistance to IR, chemotherapy and
cytotoxic cytokines.
Our previous and current data suggest that
targeting Stat1, IL6 and IL8 may enhance the
therapeutic ratio for treatment of Stat1 over-
expressing tumours.
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